Abstract

BackgroundRecently, it has been reported that angiotensin II receptor-associated protein (AGTRAP) plays a substantial role in tumor progression. Nevertheless, the possible role of AGTRAP in hepatocellular carcinoma (HCC) remains unrecognized.MethodsThe metabolic gene rapid visualizer, Cancer Cell Line Encyclopedia, Human Protein Atlas, and Hepatocellular Carcinoma Database were used to analyze the expression of AGTRAP in HCC tissues and normal liver tissues or adjacent tissues. Kaplan-Meier plotter and UALCAN analysis were used to assess the prognostic and diagnostic value of AGTRAP. LinkedOmics and cBioPortal were used to explore the genes co-expressed with AGTRAP in HCC. To further understand the potential mechanism of AGTRAP in HCC, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment pathway analyses were performed using R software, the protein-protein interaction (PPI) network was established using the STRING database, and the immune infiltration and T-cell exhaustion related to AGTRAP were explored via Timer and GEPIA. In addition, immunohistochemistry was used to detect the expression of AGTRAP protein in HCC tissues and paired adjacent tissues from clinical specimens.ResultsThis study found that the mRNA and protein levels of AGTRAP in HCC tissues were higher than those in normal liver tissues and adjacent tissues, and higher mRNA levels of AGTRAP were associated with higher histological grade and a poor overall survival in HCC patients. The area under the receiver operating characteristic curve (AUC) of AGTRAP was 0.856, suggesting that it could be a diagnostic marker for HCC. Moreover, the alteration rate of AGTRAP in HCC was 8%, and AGTRAP was involved in HCC probably through the NF-κB and MAPK signaling pathways. Furthermore, AGTRAP was positively correlated with the infiltration of CD8+ T cells, CD4+ T cells, B cells, macrophages, dendritic cells, and neutrophils, and the levels of AGTRAP were significantly correlated with T-cell exhaustion biomarkers. The immunohistochemistry results confirmed that the protein levels of AGTRAP were consistently higher in HCC tissues than in paired adjacent tissues.ConclusionThe clinical value of AGTRAP and its correlation with immune infiltration in HCC was effectively identified in clinical data from multiple recognized databases. These findings indicate that AGTRAP could serve as a potential biomarker in the treatment of HCC, thereby informing its prognosis, diagnosis, and even immunotherapy.

Highlights

  • Hepatocellular carcinoma (HCC) is the fourth most common malignant tumor worldwide [1] with low overall survival (OS) of patients and poor prognosis [2]

  • As assessed through an array of cancer cell lines, Angiotensin II receptor-associated protein (AGTRAP) was highly expressed in HCC cells (Figure 1B)

  • The mRNA and protein levels of AGTRAP in HCC tissues were higher than those in normal liver tissues or adjacent tissues, and higher mRNA levels of AGTRAP were associated with higher histological grade and poor overall survival (OS) time in HCC patients

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the fourth most common malignant tumor worldwide [1] with low overall survival (OS) of patients and poor prognosis [2]. Angiotensin II receptor-associated protein (AGTRAP) is localized in the perinuclear vesicle structure and the plasma membrane [4]. Sanz-Pamplona et al [7] found that AGTRAP is overexpressed in colon cancer and positively correlates with a poor prognosis. Figueiredo et al [8] reported that AGTRAP-BRAF gene fusion was detected in gastric cancer, indicating a possible role of AGTRAP in tumor progression. It has been reported that angiotensin II receptor-associated protein (AGTRAP) plays a substantial role in tumor progression. The possible role of AGTRAP in hepatocellular carcinoma (HCC) remains unrecognized

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.